VALLEY FORGE, Pa.--(BUSINESS WIRE)--Dec. 19, 2016--
AmerisourceBergen Corporation (NYSE: ABC) today announced that Keri
Mattox will join the Company as Vice President, Corporate & Investor
Relations, effective January 3, 2017. In this role, Ms. Mattox will
assume responsibility for the Company’s relationships with the analyst
and investor community, reporting directly to Tim G. Guttman, Executive
Vice President and Chief Financial Officer.
Ms. Mattox succeeds Barbara A. Brungess, currently Vice President,
Corporate & Investor Relations, who has announced that she is leaving
the Company, effective December 31, 2016, to pursue other opportunities.
“I am delighted to have Keri lead our investor relations efforts going
forward. In addition to the investor relations and healthcare industry
experience she brings to AmerisourceBergen, Keri has established a great
reputation and many strong relationships across the financial
community,” said Steven H. Collis, Chairman, President and Chief
Executive Officer of AmerisourceBergen. “We look forward to Keri’s
contributions and support as AmerisourceBergen continues to pursue its
long-term growth strategies in the global pharmaceutical supply chain.”
“I also want to thank Barbara for her leadership and dedication to
AmerisourceBergen during the 16 years she has been with the Company,”
Collis continued. “Barbara has made a significant impact on
AmerisourceBergen during her tenure and helped us build and solidify
relationships with the investment community. Her integrity, sound
judgment and industry expertise have served AmerisourceBergen and our
shareholders extremely well. It has been a pleasure working with
Barbara, and we wish her all the best.”
Ms. Mattox brings over 15 years of investor relations and corporate
communications experience spanning both corporate roles and public
relations firms. She has significant experience within the specialty,
generics and biotech pharmaceutical sectors. Most recently, Ms. Mattox
served as Senior Vice President, Investor Relations & Corporate Public
Affairs with Endo International, a role she assumed in 2015 following
Endo’s acquisition of Auxilium Pharmaceuticals, where she led the
investor relations function. At Endo, she was responsible for investor
relations, corporate communications and government affairs. Ms. Mattox
started her career in journalism with positions at the Washington Post
and Hearst Newspapers before transitioning into public relations and
then the pharmaceutical industry.
Ms. Mattox graduated magna cum laude with a bachelor’s degree in
Political Science from Boston University and has her master’s degree in
Journalism from the University of Maryland.
As of January 3, 2017, Ms. Mattox can be reached at AmerisourceBergen at
610-576-7801 and [email protected].
In the interim period, Investor Relations questions can be directed to
Bennett Murphy, Manager, Corporate & Investor Relations at 610-727-3693
and [email protected].
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel in human and animal health. With over $145 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 19,000 people. AmerisourceBergen is ranked #12 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as "expect," "likely," "outlook," "forecast," "would,"
"could," "should," "can," "will," "project," "intend," "plan,"
"continue," "sustain," "synergy," "on track," "believe," "seek,"
"estimate," "anticipate," "may," "possible," "assume," variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management's
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: competition;
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; unfavorable trends in
brand and generic pharmaceutical pricing, including in rate or frequency
of price inflation or deflation; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; changes to the customer or supplier mix; the
retention of key customer or supplier relationships under less favorable
economics or the adverse resolution of any contract or other dispute
with customers or suppliers; changes to customer or supplier payment
terms; the disruption of AmerisourceBergen's cash flow and ability to
return value to its stockholders in accordance with its past practices;
risks associated with the strategic, long-term relationship between
Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with
respect to the pharmaceutical distribution agreement and/or the global
sourcing arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact prescription
drug reimbursement under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; federal and state
prosecution of alleged violations of related laws and regulations, and
any related litigation, including shareholder derivative lawsuits or
other disputes relating to our distribution of controlled substances;
increased federal scrutiny and qui tam litigation for alleged violations
of fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale, purchase and/or dispensing of
pharmaceutical products or services and any related litigation; material
adverse resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do not
perform as expected, or that are difficult to integrate or control,
including the integration of PharMEDium, or the inability to capture all
of the anticipated synergies related thereto; regulatory action in
connection with the production, labeling or packaging of products
compounded by our compounded sterile preparations (CSP) business;
declining economic conditions in the United States and abroad; financial
market volatility and disruption; the loss, bankruptcy or insolvency of
a major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance with
the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; malfunction, failure or
breach of sophisticated information systems to operate as designed;
risks generally associated with data privacy regulation and the
international transfer of personal data; changes in tax laws or
legislative initiatives that could adversely affect AmerisourceBergen's
tax positions and/or AmerisourceBergen's tax liabilities or adverse
resolution of challenges to AmerisourceBergen's tax positions; natural
disasters or other unexpected events that affect AmerisourceBergen's
operations; the impairment of goodwill or other intangible assets,
resulting in a charge to earnings; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting
AmerisourceBergen's business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company’s Annual Report on
Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in
that report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161219005195/en/
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Tim Guttman, 610-727-7000